Health authorities in the United States have called for the suspension of the use of the Johnson & Johnson vaccine, due to reports of rare cases of blood clots.
The US Food and Drug Administration said it was calling for a suspension of the use of the vaccine “out of great caution.”
And the administration indicated that 6 cases of severe blood clots were detected among more than 6.8 million doses of the vaccine.
This recommendation comes after recording rare cases similar to AstraZeneca vaccine, which led some people to slow down in using it.
In a series of tweets on Twitter, the administration said that it and the CDC are reviewing “six rare and severe cases of blood clots registered in the United States.”
She added, “We recommend that the use of this vaccine be suspended, out of great caution.”
She indicated that this is with the aim of “ensuring that the health care delivery community is aware of the consequences of these adverse events.”
The Food and Drug Administration clarified that this type of blood clot requires treatment different from the usual treatment in similar cases.
All six injuries were of women, between the ages of 18 and 48.
The New York Times quoted officials as saying that one woman had died, while another was in critical condition in Nebraska.
Safety is a top priority
A joint statement issued by the Food and Drug Administration and the Centers for Disease Control stated that everyone who received the Johnson & Johnson vaccine and then felt severe headache or pain in the abdomen or leg, or shortness of breath within three weeks of vaccination, are invited to contact the attending physician.
The American company Johnson & Johnson issued a statement saying that safety is a “top priority”, and that it informs health authorities of “all reports of complications.”
The statement added: “We are aware of the reports of blood clots that were recorded after receiving the Covid 19 vaccine, but a causal relationship between these rare cases and the Johnson & Johnson vaccine against Covid 19 has not been proven so far.”
The company said it will continue to work with health authorities.
Health authorities have recorded very rare cases of blood clots as well, after tens of millions received the Oxford-AstraZeneca vaccine.
The reports prompted many countries to suspend the use of the vaccine, but after that, they resumed vaccination. However, some countries have restricted age groups that receive Oxford-AstraZeneca, such as adults over 60 in Germany.
In Britain, health authorities recommended that those under thirty years of age receive another vaccine.